# Nuclide record durvalumab (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/durvalumab/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "durvalumab" ;
  schema:name "Durvalumab"@en ;
  schema:description "A PD-L1 blocker that became standard after chemoradiation for stage III lung cancer, and now in bladder, biliary, and gastric cancers."@en ;
  schema:url <https://nuclide.cc/drugs/durvalumab/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Durvalumab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q19904005> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Durvalumab> ;
  nuclide:status "approved" ;
  nuclide:modality "Monoclonal antibody (anti-PD-L1)" ;
  schema:alternateName "Imfinzi" ;
  nuclide:approval "US 2017: Locally advanced or metastatic urothelial carcinoma after platinum (accelerated; indication withdrawn 2021)", "US 2018: Unresectable stage III NSCLC after chemoradiation", "US 2026: High-risk NMIBC with BCG" ;
  nuclide:indications <https://nuclide.cc/indications/sclc/>, <https://nuclide.cc/indications/hcc/>, <https://nuclide.cc/indications/hcc-intermediate/> ;
  nuclide:companies <https://nuclide.cc/companies/astrazeneca/> ;
  nuclide:trials <https://nuclide.cc/trials/nct05063565/>, <https://nuclide.cc/trials/nct06040099/> .